15 10, 2024

Eager to lern more about differential miRNA expression patterns in Type 2 diabetes mellitus

2024-10-15T07:46:12+02:00October 15th, 2024|biomarker, bone diseases, bone fracture risk assessment, diabetes, microRNA services, microRNAs, miND spike ins, NGS, sequencing, smallRNA|0 Comments

Excited to share our latest study on the link between Type 2 Diabetes Mellitus (T2DM) and bone fragility using miRNA profiling in a polygenic mouse model! 🧬🦴 🔍 Research Highlights: We utilized an unbiased genome-wide approach to identify dysregulated miRNAs in serum, bone marrow, and bone of the TallyHo/JngJ (TH) mouse model, which closely mirrors T2DM in humans. Key findings include upregulation of miRNAs such as mmu-miR-466i-5p and mmu-miR-1195 in both serum and bone marrow of diabetic mice. Dysregulated miRNAs were linked to pathways associated with diabetes-related signaling and diabetic bone disease, shedding light on potential mechanistic pathways. Cell-type enrichment analysis pointed towards miRNAs enriched in specific cell types like immune cells, hepatocytes, and mesenchymal stem cells, [...]

18 09, 2024

Eager to lern more about neuron-derived extracellular vesicles as predictive biomarkers

2024-09-18T14:10:09+02:00September 18th, 2024|biomarker, biomarkers, exosomes, microRNA services, microRNAs, miND spike ins, NGS, sequencing, smallRNA|Comments Off on Eager to lern more about neuron-derived extracellular vesicles as predictive biomarkers

A new study from the University of Trieste explores the potential of microRNA (miRNA) profiles in neuron-derived extracellular vesicles (NDEVs) as predictive biomarkers for adverse drug reactions (ADRs) in children receiving ketamine. This research, leveraging TAmiRNA's Next-Generation Sequencing (NGS)-based miND® pipeline, identified specific miRNAs (miR-18a-3p, miR-484, and miR-548az-5p) as potential tools to predict ketamine-induced ADRs. This breakthrough not only advances our understanding of ketamine's side effects in children but also demonstrates the biomarker potential of organ-specific EVs and their miRNA cargo. Interested in our of extracellular vesicles (EVs) and exosomes services - click here! click here to read the paper

6 09, 2024

TAmiRNA at EUROTOX 2024 in Copenhagen

2024-09-11T08:35:27+02:00September 6th, 2024|biomarker, biomarkers, drug-induced pancreatic injury, microRNAs, miND, miND spike ins, NGS, small RNA-sequencing, TransBioLine|Comments Off on TAmiRNA at EUROTOX 2024 in Copenhagen

On September 10, our CEO & CSO, Dr. Matthias Hackl, will discuss “Small RNA-sequencing based discovery of microRNAs for CNS-injury biomarkers” during the EUROTOX Short Orals Session. He’ll highlight the efforts of TAmiRNA and the IMI consortium TransBioLine in advancing microRNAs as biomarkers of drug-induced brain injury. TAmiRNA will also bring a poster (P06-01) to the conference, authored by Senior Scientist, Dr. Kseniya Khamina-Kotisch, on “NGS-based discovery of microRNA biomarkers of drug-induced pancreatic injury (DIPI),” showcasing the merits of small RNA-sequencing (miND) for biomarker discovery. Don’t miss this opportunity to explore TAmiRNA's latest advancements in microRNA diagnostics. Reach out to Matthias directly to meet and discuss our latest developments and how TAmiRNA's  services can assist your business! TAmiRNA [...]

2 09, 2024

TAmiRNA at SSCC/SGK in Zürich

2024-09-11T08:36:01+02:00September 2nd, 2024|biomarker, biomarkers, exosomes, extracellular vesicle, microRNAs, miND spike ins, NGS|Comments Off on TAmiRNA at SSCC/SGK in Zürich

TAmiRNA will spotlight its miND® NextGen small RNA-sequencing platform and the hepatomiR® test—Europe's first CE-IVD marked test for liver function microRNA biomarkers—at the Zürich conference. These innovations highlight TAmiRNA's strengths in microRNA diagnostic development. Dr. Matthias Hackl, CEO and Chief Scientific Officer, will present "MicroRNAs as a Novel Class of Biomarkers" on Friday, September 6, in Session 6: New Technologies. He will discuss the critical role of miRNA biomarkers and TAmiRNA's advanced sequencing techniques, which speed up the discovery of novel biomarker associations. Don’t miss this opportunity to explore TAmiRNA's latest advancements in microRNA diagnostics. Reach out to Matthias directly to meet and discuss our latest developments and how TAmiRNA's  services can assist your business! TAmiRNA [...]

9 08, 2024

Eager to lern more about Early Detection of Colorectal Cancer through MicroRNA Profiling

2024-08-09T11:17:20+02:00August 9th, 2024|biomarker, biomarkers, exosomes, microRNA services, microRNAs, miND spike ins, NGS, sequencing, smallRNA|Comments Off on Eager to lern more about Early Detection of Colorectal Cancer through MicroRNA Profiling

TAmiRNA and its partner Biomedica are proud to announce that researchers from the Jagiellonian University Medical College used our innovative small RNA-sequencing pipeline (miND®) to unravel novel miRNA expression profiles in colorectal cancer cell lines and the extracellular vesicles (EVs) they produce. Colorectal cancer ranks as the third most common cancer in men and the second in women globally. Late diagnosis significantly contributes to rising morbidity and mortality rates, emphasizing the urgent need for new markers for early and precise detection. The analysis of miRNAs in plasma-derived EVs and tumor samples from CRC patients revealed a similar miRNA expression profile between patient samples and CRC cell lines. Importantly, miR-182-5p, miR-196b-5p, miR-425-5p, and miR-429 were found regulated in [...]

18 06, 2024

TAmiRNA at SelectBIO Congress Rotterdam

2024-09-11T08:36:38+02:00June 18th, 2024|biomarker, biomarkers, exosomes, extracellular vesicle, microRNAs, miND spike ins, NGS|Comments Off on TAmiRNA at SelectBIO Congress Rotterdam

TAmiRNA CEO/CSO Matthias Hackl and scientst Marianne Pultar will attend the SelectBIO Congress Rotterdam next week and will showcase its services at Booth E5 in the Exhibition Zone at the Hilton Rotterdam. TAmiRNA will also be a scientific contributor to the conference with a poster presentation on how to leverage extracellular vesicle microRNA cargo to enable in-vivo tracing of EVs based on their unique cargoes (biodistribution). Reach out to Matthias and Marianne directly to meet and discuss our latest developments and how TAmiRNA's  services can assist your business! TAmiRNA CEO Dr. Matthias Hackl

4 04, 2024

Exciting news!

2024-04-04T13:16:30+02:00April 4th, 2024|biomarker, biomarkers, Illumina NewSeq2000, microRNA services, microRNAs, miND spike ins, NGS, sequencing, smallRNA|Comments Off on Exciting news!

We just received the Illumina NextSeq 2000 machine, marking a significant milestone in our journey towards cutting-edge research and innovation. This powerful instrument will drive our NGS services and allow us to deliver results quicker than ever before.

5 03, 2024

TAmiRNA at RNA Leaders conference in Basel

2024-03-05T08:19:26+01:00March 5th, 2024|biomarker, biomarkers, microRNAs, NGS|Comments Off on TAmiRNA at RNA Leaders conference in Basel

TAmiRNA CEO/CSO Matthias Hackl will attend the RNA Leaders conference in Basel next week to speak about the recent development of reliable miRNA safety biomarkers and their potential to indicate injury of the liver, kidneys, pancreas, blood vessels, and central nervous system for drug development purposes. Reach out to Matthias directly to meet with him before or after his presentation on Wednesday, March 13th at 12:25 pm and discuss our latest developments and how TAmiRNA's  services can assist your business!

13 02, 2024

Webinar – COST Action AtheroNET

2024-02-13T11:20:12+01:00February 13th, 2024|biomarker, biomarkers, exosomes, extracellular vesicle, microRNA, microRNA services, microRNAs, quality, sequencing, smallRNA|Comments Off on Webinar – COST Action AtheroNET

Looking forward to sharing our insights from 10+ years of extracellular microRNA (and recently long RNA as well) biomarker discovery and diagnostic test development with the COST Action AtheroNET group. Date: 19.02.2024 Time: 19:30 CET Registration Link: https://lnkd.in/dVDDYKcA Reach out to Matthias directly after his webinar and discuss our latest developments and how TAmiRNA’s  miND spike ins and small RNA sequencing service can assist your business!

26 01, 2024

TAmiRNA ‘2023 In Review’

2024-01-26T11:44:38+01:00January 26th, 2024|biomarker, biomarkers, exosomes, extracellular vesicle, ISO 13485, Liver disease, microRNA, microRNA services, microRNAs, quality, sequencing, smallRNA|Comments Off on TAmiRNA ‘2023 In Review’

One last look back at 2023 before we turn our attention to our goals for 2024: last year brought us progress in many areas, from the development of new laboratory and data analyses to the implementation of hepatomiR® in routine clinical diagnostics and the establishment of important partnerships. Our thanks go to the entire (growing) TAmiRNA team, and our customers and partners! We look forward to working together and to our joint successes in 2024!

Go to Top